



## AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

### Descrizione

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE

SHANGHAI, Feb. 10, 2026 /PRNewswire/ â?? AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows from early development to commercial manufacturing.

AsymBio is a technology-driven biopharmaceutical CDMO focused on accelerating innovation through integrated development and manufacturing services for clients. Key platforms include:

AsymBio will continue to invest in R&D and technology development through advanced technology platforms and data-enabled manufacturing processes. By integrating advanced scientific approaches with large-scale manufacturing experience, AsymBio works to help global clients address complex development challenges, improve manufacturing efficiency and product quality, and support reliable commercialization of innovative therapies.

#### About AsymBio

AsymBio focuses exclusively on biopharmaceutical CDMO services. The company delivers one-stop CDMO services from early-stage development to clinical, toxicology, and commercial-scale manufacturing. AsymBio is also expanding beyond ADCs into NDCs while maintaining comprehensive capabilities for antibody therapeutics and recombinant proteins.

For more information, visit [www.asymbio.com](http://www.asymbio.com) or follow us on LinkedIn. Business inquiries: [MKT@asymchem.com.cn](mailto:MKT@asymchem.com.cn)

Logo â?? [https://mma.prnewswire.com/media/2888481/5775993/AsymBio\\_Logo.jpg](https://mma.prnewswire.com/media/2888481/5775993/AsymBio_Logo.jpg)

---

View original content:<https://www.prnewswire.co.uk/news-releases/asymbio-establishes-integrated-technology-platforms-spanning-the-full-biopharmaceutical-development-lifecycle-302682462.html>

Copyright 2026 PR Newswire. All Rights Reserved.

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE: Immediapress Ã? un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dallâ?ente che lo emette. Lâ?Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

â??

[immediapress/pr-newswire](https://www.immediapress/pr-newswire)

### Categoria

1. Comunicati

### Tag

1. ImmediaPress

### Data di creazione

Febbraio 10, 2026

### Autore

redazione

*default watermark*